ProCE Banner Activity

ASCEMBL: 48-Wk Update of Results From the Phase III Study of STAMP Inhibitor Asciminib vs Bosutinib for CML-CP Previously Treated With ≥2TKIs

Slideset Download
Conference Coverage
Sustained superior efficacy of asciminib vs bosutinib at Week 48 in the ASCEMBL trial among patients with CML-CP previously treated with ≥2 TKIs.

Released: December 14, 2021

Expiration: December 13, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation